I am a shareholder and supporter of this company, however I believe creating unrealistic expectations regarding potential can lead to damage rather than value creation. It is IMHO woefully optimistic to think NEU's FX treatment will generate $100K per patient. The drug hopefully will treat several but by no means all symptoms of what is a spectrum disorder. There are existing treatments eg for the anxiety component. The condition is not fatal, nor aggressively degenerative like Retts. More like $10K-$15K in my opinion. Still a very significant market close to a $USD1bn. And then the follow-on possibility of more widely treating autism.
Zen
Fragile X opportunity much smaller
-
- There are more pages in this discussion • 41 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.05 |
Change
-0.510(3.50%) |
Mkt cap ! $1.795B | |||
| Open | High | Low | Value | Volume |
| $14.38 | $14.42 | $13.94 | $6.419M | 454.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $13.99 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.07 | 6644 | 4 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |